3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
15
Recruiting
12
Active not recruiting
10
Terminated
3
Withdrawn
2
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Carcinoma, Non-Small-Cell Lung
13
Melanoma
11
Triple Negative Breast Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Neoplasms
7
Head and Neck Neoplasms
7
Multiple Myeloma
6
Carcinoma, Transitional Cell
6
Carcinoma, Renal Cell
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Recurrence
3
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Kidney Neoplasms
2
Inflammatory Breast Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Urothelial Cancer
1
Thyroid Neoplasms
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Spinocerebellar Degenerations
1
Interventions
Radiotherapy
5
Gemcitabine
4
Cyclophosphamide
4
pazopanib
3
Docetaxel
3
Biopsy
3
pembrolizumab
2
olaparib
2
liposomal doxorubicin
2
Vincristine
2
Trastuzumab
2
Trabectedin
2
Temozolomide
2
Taxes
2
Surgical Procedures, Operative
2
Specimen Handling
2
Proton Therapy
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ifosfamide
2
Filgrastim
2
Etoposide
2
Drug Therapy
2
Doxorubicin
2
Celecoxib
2
Carboplatin
2
Ascorbic Acid
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
trastuzumab biosimilar HLX02
1
tozuleristide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Sarcoma
×
pembrolizumab
×
Clear all
NCT06116578
2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Withdrawn
NCT06494787
2025-02-24
SOC-2320
Sarcoma Oncology Research Center, LLC
Phase 2
Withdrawn